Our results indicated that serum thioredoxin could complement measurement of AFP in the diagnosis of HCC, especially very early disease, and will help to resolve the deficiencies of AFP in the testing of AFP-negative patients. This evidence concerns the gene TXN and hepatocellular carcinoma.